To demonstrate definitively that biomarkers improve diagnostic accuracy of an accompanying neurodegenerative cognitive disease in people with MS would require a more rigorous evaluation of pwMS and cognitive impairment with a standard set of biomarker evaluations (including brain PET and CSF amyloid and tau) and follow-up each to neuropathological autopsy evaluation. Here, MAPT is linked to Cognitive impairment.